Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2016. Centers for Disease Control and Prevention website. http://wonder.cdc.gov. Accessed May 29, 2019.
Prescription opioid data. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugoverdose/data/prescribing.html. Updated December 19, 2018. Accessed May 29, 2019.
Ahmad FB, Escobedo LA, Rossen LM, et al. Provisional drug overdose death counts. National Center for Health Statistics. 2019. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm#notes. Accessed August 4, 2019.
Katz J. The first count of fentanyl deaths in 2016: up 540% in three years. NY Times. September 2, 2017. https://www.nytimes.com/interactive/2017/09/02/upshot/fentanyl-drug-overdose-deaths.html. Accessed June 5, 2019.
Fentanyl. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugoverdose/opioids/fentanyl.html. Updated December 19, 2018. Accessed June 1, 2019.
CDC National Center for Injury Prevention and Control. Prescription Behavior Surveillance System. Issue brief. July 2017.
Suzuki J, El-Haddad S. A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend. 2017;171:107-116.
Controlled substances schedules. Drug Enforcement Administration. Diversion Control Division website. https://www.deadiversion.usdoj.gov/schedules/. Accessed May 29, 2019.
Boadas-Vaello P, Castany S, Homs J et al. Neuroplasticity of ascending and descending pathways after somatosensory system injury: reviewing knowledge to identify neuropathic pain therapeutic targets. Spinal Cord. 2016;54:330-340.
Le Merrer J, Becker JA, Befort K, Kieffer BL. Reward processing by the opioid system in the brain. Physiol Rev. 2009;89:1379-1412.
Toll L, Borsodi A, Bruchas M et al. Opioid receptors, introduction. IUPHAR/BPS Guide to PHARMACOLOGY. Updated October 8, 2015. Accessed August 8, 2019. https://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=50. Accessed August 8, 2019.
Polunina AG, Bryun EA. Neuropsychological functions of μ- and δ-opioid systems. ISRN Addict. 2013;2013:674534.
Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002.
Aydede M, Shriver A. Recently introduced definition of “nociplastic pain” by the International Association for the Study of Pain needs better formulation. Pain. 2018;159:1176-1177.
Kosek E, Cohen M, Baron R, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016;157:1382-1386.
Matteliano D, St. Marie B, Oliver J, et al. Adherence monitoring with chronic opioid therapy for persistent pain. Pain Manag Nurs. 2014;15:391-405.
Cánovas L, Carrascosa AJ, García M, et al. Impact of empathy in the patient-doctor relationship on chronic pain relief and quality of life: a prospective study in Spanish pain clinics. Pain Med. 2018;19:1304-1314.
Taub CJ, Sturgeon JA, Johnson KA, et al. Effects of a pain catastrophizing induction on sensory testing in women with chronic low back pain: a pilot study. Pain Res Manag. 2017;2017:7892494.
Gatchel RJ, Neblett R. Pain catastrophizing: what clinicians need to know. Practical Pain Management. 2015;15. https://www.practicalpainmanagement.com/pain/other/co-morbidities/pain-catastrophizing-what-clinicians-need-know. Accessed June 7, 2019.
Watcher K. Pain catastrophizing: what practitioners need to know. Practical Pain Management. 2019;19:22-24. https://www.practicalpainmanagement.com/treatments/psychological/pain-catastrophizing-what-practitioners-need-know. Accessed June 7, 2019.
Zacharoff KL, McCarberg BH, Reisner L, et al. Managing Chronic Pain with Opioids in Primary Care. 2nd ed. Newton, MA: Inflexion, Inc., 2010.
Heapy A, Kerns RD. Psychological and Behavioral Assessment. In: Benzon HT, Rathmell JP, Wu CL, Turk DC, Argoff CE, eds. Raj's Practical Management of Pain. 4th ed. Philadelphia, PA: Mosby-Elsevier; 2008;279-295.
Doheny K. Better approach to pain assessment places emphasizes on function. Practical Pain Management. https://www.practicalpainmanagement.com/resources/news-and-research/better-approach-pain-assessment-places-emphasizes-function. January 28, 2018. Accessed May 29, 2019.
Friction J, Gupta A, Weisberg MB, et al. Can we prevent chronic pain? Practical Pain Management. 15. https://www.practicalpainmanagement.com/treatments/can-we-prevent-chronic-pain. Updated September 27, 2017. Accessed June 18, 2019.
Gelot S, Nakhla E. Opioid dosing in renal and hepatic impairment. US Pharm. 2014;39:34-38. https://www.uspharmacist.com/article/opioid-dosing-in-renal-and-hepatic-impairment. Accessed June 6, 2019.
Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113-130.
Lalani I, Argoff CE. History and Physical Examination of the Pain Patient. In: Benzon HT, Rathmell JP, Wu CL, Turk DC, Argoff CE, eds. Raj's Practical Management of Pain. 4th ed. Philadelphia, PA: Mosby-Elsevier; 2008;177-188.
Rakel BA, Blodgett NP, Bridget Zimmerman M, et al. Predictors of postoperative movement and resting pain following total knee replacement. Pain. 2012;153:2192-2203.
Substance Abuse and Mental Health Services Administration. Prescription drug monitoring programs: a guide for healthcare providers. In Brief. 2017;10. https://store.samhsa.gov/system/files/sma16-4997.pdf. Accessed June 18, 2019.
Henry SG, Bell RA, Fenton JJ, Kravitz RL. Goals of chronic pain management: do patients and primary care physicians agree and does it matter? Clin J Pain. 2017;33:955-961.
US Food and Drug Administration. FDA Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain. Modified: September 2018.
National Center for Complementary and Integrative Health. Tai chi and qi gong: in depth. NCCIH Pub No.: D322. Updated October 2016.
Use of yoga, meditation, and chiropractic by adults and children: what the science says. National Center for Complementary and Integrative Health website. https://nccih.nih.gov/health/providers/digest/Yoga-Meditation-Chiropractic-Use-Adults-children-science. November 2018. Accessed June 2, 2019.
Luttrell MJ, Halliwill JR. The intriguing role of histamine in exercise responses. Exerc Sport Sci Rev. 2017;45:16-23.
Pain: Current Understanding of Assessment, Management, and Treatments. American Pain Society website. http://americanpainsociety.org/uploads/education/npc.pdf. 2005. Accessed June 19, 2019.
Sarbacker GB. Topical therapies for chronic pain management: a review of diclofenac and lidocaine. US Pharm. 2015;40:35-38. https://www.uspharmacist.com/article/topical-therapies-for-chronic-pain-management-a-review-of-diclofenac-and-lidocaine. Accessed June 19, 2019.
Galluzzi KE. Management of neuropathic pain. J Am Osteopath Assoc. 2005;105(9 Suppl 4):S12-S19.
Obata H. Analgesic mechanisms of antidepressants for neuropathic pain. Int J Mol Sci. 2017;18:2483.
Cheng J, Daftari A, Zhou L. Sympathetic blocks provided sustained pain relief in a patient with refractory painful diabetic neuropathy. Case Rep Anesthesiol. 2012;2012:285328.
Simpson RW, Wlodarczyk JH. Transdermal buprenorphine relieves neuropathic pain: a randomized, double-blind, parallel-group, placebo controlled trial in diabetic peripheral neuropathic pain. Diabetes Care. 2016;39:1493-1500.
Kwiatek R. Treatment of fibromyalgia. Aust Prescr. 2017;40:179-183.
Resmini G, Ratti C, Canton G, et al. Treatment of complex regional pain syndrome. Clin Cases Miner Bone Metab. 2015;12(Suppl 1):26-30.
Hadley SK, Gaarder SM. Treatment of irritable bowel syndrome. Am Fam Physician. 2005;72:2501-2508.
Centers For Disease Control and Prevention. CDC guideline for prescribing opioids for chronic pain--United States, 2016. MMWR. 2016;65:1-15.
Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10:131-146.
Kaye AD, Jones MR, Kaye AM et al. Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse: part 1. Pain Physician. 2017;20:S93-S109.
Cheatle MD, Compton PA, Dhingra L et al. Development of the revised opioid risk tool to predict opioid use disorder in patients with chronic nonmalignant pain. J Pain. 2019;20:842-851.
Passik SD, Kirsh KL, Casper D. Addiction-related assessment tools and pain management. Pain Med. 2008;(Suppl 9):S145-S166.
Rasmussen IS, Arefjord K, Winje D, et al. Childhood maltreatment trauma: a comparison between patients in treatment for substance use disorders and patients in mental health treatment. Eur J Psychotraumatol. 2018;9:1492835.
LeTendre ML, Reed MB. The effect of adverse childhood experience on clinical diagnosis of a substance use disorder: results of a nationally representative study. Subst Use Misuse. 2017;52:689-697.
Hirschtritt ME, Delucchi KL, Olfson M. Outpatient, combined use of opioid and benzodiazepine medications in the United States, 1993-2014. Prev Med Rep. 2018;9:49-54.
Baldini A, Von Korff M, Lin EH. A review of potential adverse effects of long-term opioid therapy: a practitioner's guide. Prim Care Companion CNS Disord. 2012;14.
The role of abuse-deterrent formulations in opioid abuse. Pharmacy Times. April 2019. https://s3.amazonaws.com/pharmacytimes/R997_MorphabondMarch_2019.pdf. Accessed July 19, 2019.
Mallappallil M, Sabu J, Friedman EA, et al. What do we know about opioids and the kidney? Int J Mol Sci. 2017;18:223.
Gudin J. Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012;44(6 Suppl):S4-14.
American Society of Geriatrics. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57:1331-1346.
Lind JN, Interrante JD, Ailes EC, et al. Maternal use of opioids during pregnancy and congenital malformations: a systematic review. Pediatrics. 2017;139.
The American College of Obstetrics and Gynecology. Opioid use and opioid use during pregnancy. ACOG Committee Opinion. Number 711. August 2017.
DURAGESIC (fentanyl transdermal system) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; Approved 1968. Revised September 2018.
OXYCONTIN® (oxycodone hydrochloride) extended-release tablets [prescribing information]. Stamford, CT: Purdue Pharma L.P.; Approved 1950. Revised 2014.
Berde CB, Walco GA, Krane EJ, et al. Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop. Pediatrics. 2012;129:354-364.
Cosio D, Lin EH. Disturbed sleep: causes and treatments. Practical Pain Management. 2015;15. Available at: https://www.practicalpainmanagement.com/pain/other/co-morbidities/disturbed-sleep-causes-treatments. Accessed June 3, 2019.
Safe use of opioids in hospitals. Sentinel Event Alert. Issue 49. The Joint Commission website. https://www.jointcommission.org/assets/1/18/SEA_49_opioids_8_2_12_final.pdf. August 8, 2012. Accessed June 6, 2019.
Webster LR, Reisfield GM, Dasgupta N. Eight principles for safer opioid prescribing and cautions with benzodiazepines. Postgrad Med. 2013;127:27-32.
Ammaturo DA, Hadjistavropoulos T, Williams J. Pain in dementia: use of observational pain assessment tools by people who are not health professionals. Pain Med. 2017;18:1895-1907.
Booker SQ, Haedtke C. Assessing pain in nonverbal older adults. Nursing. 2016;46:66-69.
Ross S, Peselow E. Co-occurring psychotic and addictive disorders: neurobiology and diagnosis. Clin Neuropharmacol. 2012;35:235-243.
Santucci K. Psychiatric disease and drug abuse. Curr Opin Pediatr. 2012;24:233-237.
Rastogi R, Swarm RA, Patel TA. Case scenario: opioid association with serotonin syndrome: implications to the practitioners. Anesthesiology. 2011;115:1291-1298.
US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. March 22, 2016.
Substance Abuse and Mental Health Services Administration. Clinical Drug Testing in Primary Care. Technical Assistance Publication (TAP) 32. HHS Publication No.(SMA) 12-4668. Rockville, MD: US Department of Health and Human Services; 2012.
Gourlay DL, Heit HA, Caplan YH. Urine Drug Testing in Clinical Practice. The Art and Science of Patient Care. 4th ed. San Francisco, CA: California Academy of Family Providers; 2010.
Christo PJ, Manchikanti L, Ruan X, et al. Urine drug testing in chronic pain. Pain Physician. 2011;14:123-143.
Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc. 2009;84:602-612.
Yi P, Pryzbylkowski P. Opioid induced hyperalgesia. Pain Medicine. 2015;16:S32-S36.
Adesoye A, Duncan N. Acute pain management in patients with opioid tolerance. US Pharm. 2017;42:28-32. https://www.uspharmacist.com/article/acute-pain-management-in-patients-with-opioid-tolerance. Accessed June 20, 2019.
The neurobiology of drug addiction. National Institute on Drug Abuse website. https://www.drugabuse.gov/node/pdf/1922/the-neurobiology-of-drug-addiction. January 2007. Accessed June 7, 2019.
Fine PG, Portenoy RK; Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing "best practices" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38:418-425.
Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38:426-439.
Pasternak GW. Multiple opiate receptors: deja vu all over again. Neuropharmacology. 2004;47(Suppl 1):312-323.
Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain. 2014;15:321-337.
Periyakoil V. Palliative Care Online Curriculum. Opioid Conversion: Equivalency Table. https://palliative.stanford.edu/opioid-conversion/equivalency-table/. Accessed June 20, 2019.
Shaheen PE, Walsh D, Lasheen W, et al. Opioid equianalgesic tables: are they all equally dangerous? J Pain Symptom Manage. 2009;38:409-417.
Webster LR, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicity. Pain Med. 2012;13:562-570.
Haffey F, Brady RR, Maxwell S. A comparison of the reliability of smartphone apps for opioid conversion. Drug Saf. 2013;36:111-117.
FDA issues draft guidance on abuse-deterrent formulations of generic opioids. US Food and Drug Administration website. https://www.fda.gov/drugs/information-drug-class/fda-issues-draft-guidance-abuse-deterrent-formulations-generic-opioids. March 24, 2016. Accessed June 7, 2019.
Institute for Clinical and Economic Review. Abuse-Deterrent Formulations of Opioids: Effectiveness and Value. Final Evidence Report. August 8, 2017.
Bettinger JJ, Archer K, Wegrzyn EL, Fudin J. Demystifying opioid abuse-deterrent technologies. Practical Pain Management. 2018;18. https://www.practicalpainmanagement.com/treatments/pharmacological/opioids/demystifying-opioid-abuse-deterrent-technologies. Accessed June 9, 2019.
Gourlay DL, Heit HA. Universal precautions revisited: managing the inherited pain patient. Pain Med. 2009;10(Suppl 2):S115-S123.
Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6:107-112.
Gugelmann HM, Perrone J. Can prescription drug monitoring programs help limit opioid abuse? JAMA. 2011;306:2258-2259.
Gourlay D, Heit HA. The art and science of urine drug testing. Clin J Pain. 2010;26:358.
Nafziger AN, Bertino JS Jr. Utility and application of urine drug testing in chronic pain management with opioids. Clin J Pain. 2009;25:73-79.
Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manage. 2004;27:260-267.
Lötsch J, Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med. 2005;11:82-89.
Reisfield GM, Chronister CW, Goldberger BA, et al. Unexpected urine drug testing results in a hospice patient on high-dose morphine therapy. Clin Chem. 2009;55:1765-1768.
Wasan AD, Michna E, Janfaza D, et al. Interpreting urine drug tests: prevalence of morphine metabolism to hydromorphone in chronic pain patients treated with morphine. Pain Med. 2008;9:918-923.
Chen YL, Hanson GD, Jiang X, et al. Simultaneous determination of hydrocodone and hydromorphone in human plasma by liquid chromatography with tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;769:55-64.
Oyler JM, Cone EJ, Joseph RE Jr., et al. Identification of hydrocodone in human urine following controlled codeine administration. J Anal Toxicol. 2000;24:530-535.
Cone EJ, Caplan YH. Urine toxicology testing in chronic pain management. Postgrad Med. 2009;121:91-102.
Sloan PA, Barkin RL. Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. J Opioid Manag. 2008;4:131-144.
Compton PA, Wu SM, Schieffer B, et al. Introduction of a self-report version of the Prescription Drug Use Questionnaire and relationship to medication agreement noncompliance. J Pain Symptom Manage. 2008;36:383-395.
Agerwala SM, McCance-Katz EF. Integrating screening, brief intervention, and referral to treatment (SBIRT) into clinical practice settings: a brief review. J Psychoactive Drugs. 2012;44:307-317.
Substance Abuse and Mental Health Services Administration. Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders. Treatment Improvement Protocol (TIP) Series 54. HHS Publication No. (SMA) 12-4671. 2011. Rockville, MD.
Kral LA. Safely discontinuing opioid analgesics. https://www.nhms.org/sites/default/files/Pdfs/Safely_Tapering_Opioids.pdf. March 2006. Accessed June 21, 2019.
FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults. US Food and Drug Administration website. https://www.fda.gov/news-events/press-announcements/fda-approves-first-non-opioid-treatment-management-opioid-withdrawal-symptoms-adults. May 16, 2018. Accessed June 26, 2019.
Opioid agonist therapy. Centre for Addiction and Mental Health website. https://www.camh.ca/-/media/files/oat-info-for-clients.pdf. 2016. Accessed June 4, 2019.
McDonald EM, Kennedy-Hendricks A, McGinty EE et al. Safe storage of opioid pain relievers among adults living in households with children. Pediatrics. 2017;139.
Disposal of unused medicines: what you should know. US Food and Drug Administration website. https://www.fda.gov/drugs/safe-disposal-medicines/disposal-unused-medicines-what-you-should-know. May 30, 2019. Accessed June 21, 2019.
Public Policy Statement: Short Definition of Addiction. American Society of Addiction Medicine website. https://www.asam.org/docs/default-source/public-policy-statements/1definition_of_addiction_short_4-11.pdf?sfvrsn=6e36cc2_0. August 15, 2011. Accessed June 18, 2019.
Center for Behavioral Health Statistics and Quality. Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Use and Health, 2016. Substance Abuse and Mental Health Services Administration, Rockville, MD.
Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain. 2012;6:11-16.
Gardner EL. Introduction: addiction and brain reward and anti-reward pathways. Adv Psychosom Med. 2011;30:22-60.
Van Bockstaele EJ1, Reyes BA, Valentino RJ. The locus coeruleus: A key nucleus where stress and opioids intersect to mediate vulnerability to opiate abuse. Brain Res. 2010;1314:162-174.
U.S. Department of Health and Human Services (HHS), Office of the Surgeon General, Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. Washington, DC: HHS, November 2016.
Davis MA, Lin LA, Liu H, et al. Prescription opioid use among adults with mental health disorders in the United States. J Am Board Fam Med. 2017;30:407-417.
Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use -- United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66:265-269.
Gustin R, Nichols J, Martin PR. Individualizing opioid use disorder (OUD) treatment: time to fully embrace a chronic disease model. J Reward Defic Syndr. 2015;1:10-15.
How effective are medications to treat opioid use disorder? National Institute on Drug Abuse website. https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioid-addiction/efficacy-medications-opioid-use-disorder. Updated June 2018. Accessed June 24, 2019.
Methadone. Substance Abuse and Mental Health Services Administration website. https://www.samhsa.gov/medication-assisted-treatment/treatment/methadone. Updated May 1, 2019. Accessed June 24, 2019.
Buprenorphine waiver management. Substance Abuse and Mental Health Services Administration website. https://www.samhsa.gov/medication-assisted-treatment/training-materials-resources/buprenorphine-waiver. Updated May 7, 2019. Accessed June 24, 2019.
Bailey JA, Hurley RW, Gold MS. Crossroads of pain and addiction. Pain Med. 2010;11:1803-1818.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

CO*RE Faculty Advisory Panel and Contributing Faculty

David Bazzo, MD

Clinical Professor of Family Medicine
University of California, San Diego School of Medicine

Ron Crossno, MD

Ron Crossno, MD Vice President, Medical Affairs, and Chief Medical Officer at Kindred at Home

Katherine Galluzzi, DO

Professor and Chair Department of Geriatrics
Philadelphia College of Osteopathic Medicine

Carol Havens, MD

Director of Physician Education and Development
Kaiser Permanente, Northern California

Randall Steven Hudspeth, PhD, APRN

Practice and Regulation Consultant in Advanced Practice Pain Management and Palliative Care

Dennis Rivenburgh, MS, ATC, PA-C, DFAAPA

Physician Assistant at LifeBridge Health Sports Medicine Institute

Edwin A. Salsitz, MD, DFASAM

Associate Clinical Professor of Psychiatry
Icahn School of Medicine at Mount Sinai
Mount Sinai Beth Israel Medical Center

Barb St. Marie, PhD, AGPCNP, FAANP

Assistant Professor
College of Nursing, University of Iowa

Disclosures

The CO*RE Faculty Advisory Panel have disclosed no relevant financial relationships.

Editors

Kathy Merlo

Medical Education Director, Medscape, LLC

Disclosures

Disclosures: Kathy Merlo, disclosed no relevant financial relationships.

Zachary Hartman, PhD

Scientific Content Manager, Medscape

Disclosures

Disclosure: Zachary Hartman, PhD, has disclosed no relevant financial relationships.

Anjali Mehra, MD

Lead Medical Education Director, Medscape, LLC

Disclosures

Disclosures: Anjali Mehra, MD, disclosed no relevant financial relationships.

Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

CE Reviewer

Esther Nyarko, PharmD

Associate CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

AAFP Reviewer

Charles P. Vega, MD

Disclosures

Disclosure: Charles P. Vega, MD has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Genentech

CME / ABIM MOC / CE

Pain Management and Opioids: Balancing Risks and Benefits-Updated 2019-20

Authors: CO*RE Faculty Advisory Panel
CME / ABIM MOC / CE Released: 9/25/2019
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/25/2020, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for physicians, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals who are involved in the management of patients with pain.

The goal of this activity is to improve the management of patients with pain.

Upon completion of this activity, participants will have:

Increased competence related to
- Applying the pathophysiology of pain as it relates to pain management
- Accurately assessing patients with pain
- Developing a safe and effective pain treatment plan
- Identifying evidence-based non-opioid options for the treatment of pain
- Recognizing the risks and benefits associated with opioid therapy to initiate safe and judicious treatment
- Monitoring and reevaluating ongoing opioid treatment
- Recognizing behaviors that may be associated with opioid use disorder

Disclosures

CO*RE Faculty Advisory Panel and Contributing Faculty

David Bazzo, MD

Clinical Professor of Family Medicine
University of California, San Diego School of Medicine

Ron Crossno, MD

Ron Crossno, MD Vice President, Medical Affairs, and Chief Medical Officer at Kindred at Home

Katherine Galluzzi, DO

Professor and Chair Department of Geriatrics
Philadelphia College of Osteopathic Medicine

Carol Havens, MD

Director of Physician Education and Development
Kaiser Permanente, Northern California

Randall Steven Hudspeth, PhD, APRN

Practice and Regulation Consultant in Advanced Practice Pain Management and Palliative Care

Dennis Rivenburgh, MS, ATC, PA-C, DFAAPA

Physician Assistant at LifeBridge Health Sports Medicine Institute

Edwin A. Salsitz, MD, DFASAM

Associate Clinical Professor of Psychiatry
Icahn School of Medicine at Mount Sinai
Mount Sinai Beth Israel Medical Center

Barb St. Marie, PhD, AGPCNP, FAANP

Assistant Professor
College of Nursing, University of Iowa

Disclosures

The CO*RE Faculty Advisory Panel have disclosed no relevant financial relationships.

Editors

Kathy Merlo

Medical Education Director, Medscape, LLC

Disclosures

Disclosures: Kathy Merlo, disclosed no relevant financial relationships.

Zachary Hartman, PhD

Scientific Content Manager, Medscape

Disclosures

Disclosure: Zachary Hartman, PhD, has disclosed no relevant financial relationships.

Anjali Mehra, MD

Lead Medical Education Director, Medscape, LLC

Disclosures

Disclosures: Anjali Mehra, MD, disclosed no relevant financial relationships.

Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

CE Reviewer

Esther Nyarko, PharmD

Associate CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

AAFP Reviewer

Charles P. Vega, MD

Disclosures

Disclosure: Charles P. Vega, MD has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Genentech

Accreditation Statements

Presented by Medscape, a member of the Collaborative for Risk Evaluation and Mitigation Strategy (REMS) Education (CO*RE), nine interdisciplinary organizations working together to improve pain management and prevent adverse outcomes. Link

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies (RPC). Please see the document of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration.

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 3.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

This Enduring Material activity, Pain Management and Opioids: Balancing Risks and Benefits, has been reviewed and is acceptable for up to 3.0 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 09/09/2019. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Physician Assistants

Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.00 AAPA Category 1 CME credits. Approval is valid until Expiration Date. PAs should only claim credit commensurate with the extent of their participation.

Contact This Provider

For Nurses

Awarded 3.0 contact hour(s) of continuing nursing education for RNs and APNs; 3.0 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 3.0 contact hour(s) (0.300 CEUs) (Universal Activity Number: JA0007105-0000-19-027-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Family Medicine

CME / ABIM MOC / CE

Pain Management and Opioids: Balancing Risks and Benefits-Updated 2019-20

Authors: CO*RE Faculty Advisory PanelFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 9/25/2019

Valid for credit through: 9/25/2020, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Part 1: Assessing Opioid Risks and Pain

Can you recognize the different types of pain?
CO*RE Faculty Advisory Panel

Part 2: Treatment of Pain

Do you know when to use pharmacologic vs nonpharmacologic treatment to optimize outcomes?
CO*RE Faculty Advisory Panel

Part 3: Educating Patients and Caregivers

Are your patients with pain aware of the risks and benefits associated with opioids?
CO*RE Faculty Advisory Panel

Part 4: Understanding Opioid Use Disorder

Can you recognize patients at risk for opioid use disorder?
CO*RE Faculty Advisory Panel

Educational Impact Challenge

The goal of this activity is to improve the management of patients with pain.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 7

CME / ABIM MOC / CE Information

Additional Resources

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

CO*RE Faculty Advisory Panel and Contributing Faculty

David Bazzo, MD

Ron Crossno, MD

Katherine Galluzzi, DO

Carol Havens, MD

Randall Steven Hudspeth, PhD, APRN

Dennis Rivenburgh, MS, ATC, PA-C, DFAAPA

Edwin A. Salsitz, MD, DFASAM

Barb St. Marie, PhD, AGPCNP, FAANP

Editors

Kathy Merlo

Zachary Hartman, PhD

Anjali Mehra, MD

Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

CE Reviewer

Esther Nyarko, PharmD

AAFP Reviewer

Charles P. Vega, MD

CME / ABIM MOC / CE

Pain Management and Opioids: Balancing Risks and Benefits-Updated 2019-20

Target Audience and Goal Statement

Disclosures

CO*RE Faculty Advisory Panel and Contributing Faculty

David Bazzo, MD

Ron Crossno, MD

Katherine Galluzzi, DO

Carol Havens, MD

Randall Steven Hudspeth, PhD, APRN

Dennis Rivenburgh, MS, ATC, PA-C, DFAAPA

Edwin A. Salsitz, MD, DFASAM

Barb St. Marie, PhD, AGPCNP, FAANP

Editors

Kathy Merlo

Zachary Hartman, PhD

Anjali Mehra, MD

Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

CE Reviewer

Esther Nyarko, PharmD

AAFP Reviewer

Charles P. Vega, MD

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Pain Management and Opioids: Balancing Risks and Benefits-Updated 2019-20

Contents of This CME Activity

Part 1: Assessing Opioid Risks and Pain

Part 2: Treatment of Pain

Part 3: Educating Patients and Caregivers

Part 4: Understanding Opioid Use Disorder

Educational Impact Challenge